NewAmsterdam Pharma Company N.V. (NAMS) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $14.73M; Additional Paid in Capital, Common StockUSD $1.49B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $3.86M; Retained Earnings (Accumulated Deficit)USD $-874.97M.
- 2026-03-31: Common Stock, Value, IssuedUSD $14.59M; Additional Paid in Capital, Common StockUSD $1.46B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $4.22M; Retained Earnings (Accumulated Deficit)USD $-810.83M.
- 2025-12-31: Common Stock, Value, IssuedUSD $14.28M; Additional Paid in Capital, Common StockUSD $1.43B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $4.79M; Retained Earnings (Accumulated Deficit)USD $-762.39M.
- 2025-09-30: Common Stock, Value, IssuedUSD $14.11M; Additional Paid in Capital, Common StockUSD $1.40B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $4.64M; Retained Earnings (Accumulated Deficit)USD $-687.47M.
NewAmsterdam Pharma Company N.V. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs USD | Accumulated Other Comprehensive Income EUR |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.73M | $1.49B | $3.86M | $-874.97M | $631.42M | 3 month · $18.38M | (m) | (m) |
| 2026-03-31 | $14.59M | $1.46B | $4.22M | $-810.83M | $665.22M | 3 month · $18.00M | (m) | (m) |
| 2025-12-31 | $14.28M | $1.43B | $4.79M | $-762.39M | $683.43M | 12 month · $59.42M | (m) | (m) |
| 2025-09-30 | $14.11M | $1.40B | $4.64M | $-687.47M | $728.07M | 3 month · $15.01M | (m) | (m) |
| 2025-06-30 | $14.01M | $1.38B | $4.33M | $-615.46M | $778.50M | 3 month · $15.18M | (m) | (m) |
| 2025-03-31 | $13.97M | $1.36B | $4.43M | $-598.10M | $777.36M | 3 month · $15.21M | (m) | (m) |
| 2024-12-31 | $13.44M | $1.30B | $4.47M | $-558.57M | $757.50M | 12 month · $33.73M | (m) | (m) |
| 2024-09-30 | $11.44M | $829.40M | $4.42M | $-466.39M | $378.86M | 3 month · $8.01M | (m) | (m) |
| 2024-06-30 | $11.15M | $821.61M | $4.42M | $-449.75M | $387.44M | 3 month · $8.34M | (m) | (m) |
| 2024-03-31 | $11.11M | $807.01M | $4.42M | $-410.74M | $411.80M | 3 month · $7.96M | (m) | (m) |
| 2023-12-31 | $10.17M | $590.77M | $4.42M | $-316.97M | $288.39M | 12 month · $24.76M | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | $331.83M | 3 month · $5.44M | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | $373.34M | 3 month · $5.61M | (m) | -194.46M |
| 2023-03-31 | (m) | (m) | (m) | (m) | $398.41M | 3 month · $7.66M | (m) | (m) |
| 2022-12-31 | $10.05M | $555.62M | $4.42M | $-140.04M | $430.07M | 12 month · $4.33M | 12 month · $-5.79M | -119.36M |
| 2021-12-31 | (m) | (m) | (m) | (m) | $-113.82M | 12 month · $718.00K | (m) | -34.68M |
| 2020-12-31 | (m) | (m) | (m) | (m) | $-73.03M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |